Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Lung Screen Uptake Trial (Lung-SCREEN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02558101
Recruitment Status : Active, not recruiting
First Posted : September 23, 2015
Last Update Posted : June 2, 2020
Sponsor:
Collaborators:
University College London Hospitals
Homerton University Hospital NHS Foundation Trust
Information provided by (Responsible Party):
University College, London

Brief Summary:
This study tests the impact of a novel invitation strategy on attendance rates to a pre-lung cancer screening lung health check appointment. Patients will be individually randomised (1:1) to receive either control invitation materials or intervention invitation materials. Those who attend will undergo a "lung health check" and be invited to a baseline screening scan if eligibility criteria are fulfilled.

Condition or disease Intervention/treatment Phase
Lung Cancer Behavioral: Control invitation materials Behavioral: Intervention invitation materials Not Applicable

Detailed Description:

Lung cancer screening using low dose computed tomography (LDCT) scans has been shown to reduce lung cancer-specific and all-cause mortality in a large United States (US) trial, and screening is now being carried out in the US. Studies have shown that participation rates are invariably low, particularly by current smokers and those from socioeconomically deprived backgrounds; groups within which high risk candidates are overrepresented.

In this study the investigators aim to improve informed participation in screening and reduce socioeconomic and smoking-related biases in participation. The investigators will identify individuals at high risk of lung cancer; specifically adults aged 60-75 who are current or recent former smokers. Eligible individuals will be invited by their General Practitioner to a "lung health check appointment" via one of two randomly allocated invitation strategies. The control materials will be similar to those used by UK screening programmes for other cancer types. The intervention materials have been designed to reduce barriers to participation among smokers from low socioeconomic status backgrounds.

Those that attend will have a lung cancer risk assessment, and if confirmed to be eligible, will undergo a baseline LDCT scan. Data will be collected with respect to demographics, risk and various clinical and radiological outcomes.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1997 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Screening
Official Title: Randomised Controlled Trial to Test Novel Invitation Methods and Materials Targeted to Increase Informed Uptake of Lung Cancer Screening in Individuals at High Risk of Lung Cancer
Actual Study Start Date : November 2, 2015
Actual Primary Completion Date : July 7, 2017
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Control invitation materials
Invitation materials and strategy mimicking those of existing UK screening programmes for other cancer types
Behavioral: Control invitation materials

In the absence of usual care screening invitation materials, the control invitation materials and strategy are based upon the best available materials and methods of existing cancer screening programmes. These are comprised of the following:

  1. a pre-invitation letter notifying patients of the lung health check service and an information booklet mimicking those of existing screening programmes
  2. an invitation letter with a pre-scheduled appointment plus the same information booklet
  3. a reminder re-invitation letter for those who miss their appointment without cancelling

Experimental: Intervention invitation materials
A targeted, stepped and low information burden invitation strategy and materials, specifically designed to improve uptake by reducing barriers to participation among smokers from socioeconomically deprived backgrounds.
Behavioral: Intervention invitation materials
The intervention invitation strategy is comprised of the same stages of invitation materials as the control group. The two differences are i) Instead of the information booklet they will received a targeted leaflet, and ii) the invitation and reminder letters will use indirect phrasing to explain that smokers and ex-smokers are being invited. Together, these manipulations aim to deliver a targeted, stepped and low burden approach to information provision prior to the appointment.




Primary Outcome Measures :
  1. Attendance to pre-allocated Lung Health Check Appointment [ Time Frame: At an expected average of 1 year from the start of the study. ]
    Invitation to participation in the screening pilot will take place in blocks by GP practice and occur from day 1 until the end of recruitment (an estimated one year from the start of the study).


Secondary Outcome Measures :
  1. Demographics of all those invited. [ Time Frame: At an expected average of 1 year from the start of the study. ]
    Demographics of those invited to the screening pilot will take place in blocks by GP practice and occur from day 1 until the end of recruitment (an estimated one year from the start of the study).

  2. Smoking data of those attending. [ Time Frame: At an expected average of 1 year from the start of the study. ]
    This data will be recorded on enrolment of the participant to the study which will take place from 5 weeks after the start of the study until the end of recruitment (an estimated one year from the start of the study).

  3. Data on lung cancer risk of those attending. [ Time Frame: At an expected average of 1 year from the start of the study. ]
    This data will be recorded on enrolment of the participant to the study which will take place from 5 weeks after the start of the study until the end of recruitment (an estimated one year from the start of the study).

  4. Smoking data, data on lung cancer risk, symptom history and proportion of those attending that are eligible for screening. [ Time Frame: At an expected average of 1 year from the start of the study. ]
    This data will be recorded on enrolment of the participant to the study which will take place from 5 weeks after the start of the study until the end of recruitment (an estimated one year from the start of the study).

  5. Past medical and symptom history of those attending. [ Time Frame: At an expected average of 1 year from the start of the study. ]
    This data will be recorded on enrolment of the participant to the study which will take place from 5 weeks after the start of the study until the end of recruitment (an estimated one year from the start of the study).

  6. Proportion of those invited eligible for screening. [ Time Frame: At an expected average of 1 year from the start of the study. ]
    This data will be recorded on enrolment of the participant to the study which will take place from 5 weeks after the start of the study until the end of recruitment (an estimated one year from the start of the study).

  7. Uptake of CT scans and willingness to be screening [ Time Frame: At an expected average of 1 year from the start of the study. ]
    This data will be recorded on enrolment of the participant to the study which will take place from 5 weeks after the start of the study until the end of recruitment (an estimated one year from the start of the study).

  8. Psychological burden of screening [ Time Frame: At an expected average of 18 months from the start of the study. ]
    This data will be recorded at multiple timepoints following enrolment of the participant to the study. This will therefore occur from from 5 weeks after the start of the study until the end of recruitment (an estimated one year from the start of the study).

  9. Informed decision making [ Time Frame: At an expected average of 18 months from the start of the study. ]
    This data will be recorded at multiple timepoints following enrolment of the participant to the study. This will therefore occur from from 5 weeks after the start of the study until the end of recruitment (an estimated one year from the start of the study).

  10. Radiological and clinical outcomes of those screened [ Time Frame: At an expected average of 2 years from the start of the study. ]
  11. Numbers of investigations generated from screening [ Time Frame: At an expected average of 2 years from the start of the study. ]
  12. Costs generated from screening [ Time Frame: At an expected average of 2 years from the start of the study. ]
  13. Adverse events [ Time Frame: At an expected average of 2 years from the start of the study. ]
  14. Mortality [ Time Frame: At an expected average of 2 years from the start of the study. ]

Other Outcome Measures:
  1. Tissue bank of biological samples from a high risk cohort [ Time Frame: At an expected average of 1 year from the start of the study. ]
    This will be collected at enrolment of the participant to the study which will take place from 5 weeks after the start of the study until the end of recruitment (an estimated one year from the start of the study).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Recorded as a current smoker during the year 2010 or in subsequent years since then.

Exclusion Criteria:

  • Active diagnosis of lung cancer or metastases
  • CT thorax within the past year
  • Inability to consent to study
  • Palliative care register
  • GPs alert to co-morbidity that contraindicates screening or treatment for lung cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02558101


Locations
Layout table for location information
United Kingdom
University College London Hospital NHS Trust
London, England, United Kingdom, NW1 2BU
Sponsors and Collaborators
University College, London
University College London Hospitals
Homerton University Hospital NHS Foundation Trust
Investigators
Layout table for investigator information
Principal Investigator: Samuel Janes University College, London
Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University College, London
ClinicalTrials.gov Identifier: NCT02558101    
Other Study ID Numbers: 15/0204
First Posted: September 23, 2015    Key Record Dates
Last Update Posted: June 2, 2020
Last Verified: May 2020
Keywords provided by University College, London:
Screening
Early detection
Health inequality
Uptake
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases